UK-based pharmacogenetic testing company Genedrive PLC (AIM: GDR) announced on Monday that it has received Breakthrough Device Designation from the U.S. FDA for its Genedrive MT-RNR1 ID Kit. This point-of-care test screens infants for a genetic variant that can cause lifelong hearing loss if certain antibiotics are administered. Identified carriers can be given alternative treatments, potentially saving thousands of children from hearing impairment and reducing healthcare costs.
The FDA's Breakthrough Devices Program accelerates the development and review of medical devices that provide more effective treatment or diagnosis for life-threatening conditions. Devices must meet stringent safety and effectiveness standards for marketing authorisation.
Genedrive intends to pursue the FDA De Novo regulatory pathway for U.S. market entry, allowing the establishment of new predicate devices reflecting modern performance and safety standards. The company estimates that approximately 1,000 infants annually in U.S. Neonatal Intensive Care Units are at risk of aminoglycoside-induced hearing loss, underscoring the critical need for this test.
Genedrive is focused on developing rapid, cost-effective point-of-care solutions. Its flagship products, the Genedrive MT-RNR1 ID Kit and Genedrive CYP2C19 ID Kit, enable quick genetic diagnosis to inform treatment decisions, particularly in emergency healthcare settings. The company's commercial strategy includes maximizing in-market sales, geographic expansion and strategic M&A.
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center